Brokerages Set XOMA Royalty Corporation (NASDAQ:XOMA) Target Price at $61.60

XOMA Royalty Corporation (NASDAQ:XOMA) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $68.25.

A number of equities analysts have recently weighed in on the stock. Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Weiss Ratings restated a “hold (c-)” rating on shares of XOMA Royalty in a research report on Monday, December 29th. TD Cowen raised XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. HC Wainwright reissued a “buy” rating and issued a $97.00 target price on shares of XOMA Royalty in a research note on Friday, March 20th. Finally, Leerink Partners restated an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th.

XOMA Royalty Stock Performance

Shares of XOMA stock opened at $39.71 on Wednesday. The company has a debt-to-equity ratio of 1.15, a current ratio of 3.37 and a quick ratio of 3.37. The stock has a market cap of $473.34 million, a PE ratio of 27.20 and a beta of 0.68. The stock has a 50-day moving average of $29.20 and a 200-day moving average of $30.13. XOMA Royalty has a one year low of $20.94 and a one year high of $40.74.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings data on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.16. The business had revenue of $13.76 million for the quarter, compared to analyst estimates of $11.13 million. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%. As a group, sell-side analysts expect that XOMA Royalty will post -1.41 earnings per share for the current year.

Institutional Trading of XOMA Royalty

Several hedge funds have recently bought and sold shares of XOMA. Russell Investments Group Ltd. increased its position in shares of XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 756 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of XOMA Royalty in the 4th quarter valued at about $27,000. Tower Research Capital LLC TRC lifted its holdings in shares of XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,523 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of XOMA Royalty by 266.6% during the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after buying an additional 2,346 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after buying an additional 543 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.